InvestWiser

SynAct Pharma AB

SYNACTNasdaq StockholmHealthcareMarket value 728 m SEK
13.00SEK −5.2%
last day · Price as of 18 November 2026

The answer first

Does SynAct Pharma beat the market?

No, SynAct Pharma has not beaten the market over the last year.

SynAct Pharma−36.3%Stockholm (OMXSGI)+18.4%
  • The ranking · Quality, value and trend combined

    Better than 9% of Nordic stocks

    • Quality53
    • Value3
    • Trend24

    No. 164 of 195 in healthcare

Max for seven days

Follow SynAct Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on SynAct Pharma

From today, at a price of 13.00 SEK. Write why you follow SynAct Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about SynAct Pharma

Your first answer is free, no account needed.

Do you own SynAct Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with SynAct Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
SynAct Pharma−36.3%Stockholm (OMXSGI)+18.4%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • SynAct Pharma has fallen 36.3% over the past year, including dividends.
  • Overall, SynAct Pharma ranks better than 9% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 95.7%. The price is 90.5% below its peak now.

What do analysts think of SynAct Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

9

Quality, value and trend together. Better than 9% of Nordic stocks.

No. 164 of 195 in healthcare

Quality53
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 120 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.33
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−72.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value3
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 179 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity5.1
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend24
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 114 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−29.7%
  • 6 months−3.0%
  • 9 months−33.3%
  • 12 months−36.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−24.2%
3 years, per year
+27.5%
5 years, per year
−35.9%
10 years, per year
+9.1%
Largest fall, 3 years
−95.7%
From a peak to the bottom
From the peak now
−90.5%
How far the price is from the peak
Volatility, 1 year
70.8%
How much the price swings over a year
Beta, 1 year
0.50
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own SynAct Pharma

5 funds we follow own SynAct Pharma. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About SynAct Pharma

SynAct Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 8 employees.

SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

See the full analysis of SynAct Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market